ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 4 Issue 3, Summer 1990

June 13, 1990

AACI Opposes Most Guidelines Proposals But Can’t Agree On Research Based Ceiling

May 2, 1980

LeMaistre To Retire As M.D. Anderson President In 1996

August 18, 1995

NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use

December 7, 1984

Most Comprehensive Centers Getting Core Grants Renewed

July 27, 1990

Shaky Start For FY11 Appropriations Cycle As Congress Feels Pressure to Cut Spending

June 4, 2010